Metformin and Hyperemesis Gravidarum: Reframing a Metabolic Disorder Through the Lens of Placental Adaptation

The report by Sillis et al. [1] on the possible preventive effect of metformin against hyperemesis gravidarum (HG) provides rare, population-level insight into an under-studied condition. Their findings invite a broader reflection on whether the observed protection is purely pharmacologic or whether it reflects an adaptive metabolic response at the maternal–placental interface. Although the study benefits from real-world design and a sizable cohort, the analysis does not fully account for biological heterogeneity. Women who receive metformin differ systematically from non-users not only in body mass index (BMI) and polycystic ovarian syndrome (PCOS) status but also in mitochondrial efficiency, insulin–leptin signalling, and nutrient flux—all variables that could confound HG risk. The exposure window (“from last menstrual period to conception”) may have been too narrow to capture metabolic pre-conditioning. Future research should include biomarkers such as growth differentiation factor 15 (GDF15), fibroblast growth factor 21 (FGF21), and indices of mitochondrial stress to define mechanistically homogeneous subgroups. Recent evidence reframes HG as a disorder linked to the GDF15–GDNF family receptor alpha-like (GFRAL) axis, a nutrient-sensing pathway regulating appetite and energy balance in early gestation [2, 3]. When over-activated—particularly under mitochondrial stress—this axis can trigger severe nausea as part of a maladaptive metabolic reflex. Metformin, while known to increase GDF15 levels, also activates adenosine monophosphate-activated protein kinase (AMPK) and may promote cellular tolerance to the emetogenic drive. Whether such metabolic “training” of placental tissue lowers HG risk remains speculative but biologically plausible. A testable next step would be to compare placental AMPK and mechanistic target of rapamycin (mTOR) activity in early pregnancies exposed versus unexposed to metformin. The therapeutic enthusiasm surrounding metformin's repurposing should therefore be tempered by mechanistic uncertainty. Beyond its glycaemic effects, metformin influences trophoblast angiogenesis and oxidative stress response—processes central to placental resilience [4]. It remains unknown whether these changes translate to clinically meaningful adaptation or merely represent parallel pharmacologic effects. Several independent studies have reported that women who develop HG often exhibit subtle metabolic dysregulation, including insulin resistance and altered adipokine profiles, even in the absence of classical PCOS. Ayyavoo et al. found that offspring of mothers with severe HG had reduced insulin sensitivity, suggesting an inherited metabolic imprint [2]. Ioannidou et al. identified pre-conceptional insulin resistance and elevated BMI as consistent risk factors [3]. Together these observations support the view that HG may represent a metabolic susceptibility phenotype rather than a purely gastrointestinal disorder. In this light, Sillis et al. [1] provide more than an observational signal—they highlight a tractable model to explore how metabolic conditioning before conception might recalibrate maternal tolerance to gestational stress. Determining whether metformin modifies this adaptive threshold will require mechanistic, biomarker-driven studies rather than retrospective correlations. Nav La conceptualisation, validation, formal analysis, data curation, writing – original draft, visualisation. Schawanya K. Rattanapitoon conceptualisation, validation, formal analysis, data curation, writing – original draft, visualisation, writing – review and editing. Chutharat Thanchonnang validation, formal analysis, data curation, visualisation, writing – review and editing. Nathkapach K. Rattanapitoon validation, formal analysis, data curation, visualisation, supervision, writing – review and editing. All authors approved the final version. The authors declare no conflicts of interest. The authors have nothing to report.